NCT04550494 2026-03-19
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
8 trialsNCT04734730 2026-01-28
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
City of Hope Medical Center
Phase 2 Recruiting
NCT05873192 2025-12-23
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06844383 2025-10-29
TALENT
Prostate Cancer Clinical Trials Consortium
Phase 2 Recruiting
NCT04678362 2025-09-22
TALASUR
Centre Francois Baclesse
Phase 2 Recruiting
NCT04332744 2025-05-11
ZZ-First
MedSIR
Phase 2 Completed
NCT03148795 2024-04-05
A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer
Pfizer
Phase 2 Completed
NCT04824937 2021-04-01
Telaglenastat + Talazoparib In Prostate Cancer
Massachusetts General Hospital
Phase 2 Unknown